

PCT

13-1-1	Applicant Remarks	I hereby identify this document in a pre-conversion format and state that the international application as filed in electronic form is a complete and accurate copy of the document in the pre-conversion format. I hereby indicate that the document in the pre-conversion format is submitted under Section 706 of the Administrative Instructions under the Patent Cooperation Treaty together with the international application.
13-2-3	Validation messages Names	Green? Applicant 1: Name should preferably be entered in capital letters. Please verify.
	Validation messages Names	Green? Applicant 1: Street address missing
	Validation messages Names	Green? Applicant 1: Telephone No. missing
	Validation messages Names	Green? Applicant 1: no e-mail address has been indicated. Please verify.
	Validation messages Names	Green? Agent 1: Name should preferably be entered in capital letters. Please verify.
	Validation messages Names	Green? Inventor 1: Last name should preferably be entered in capital letters. Please verify.
	Validation messages Names	Green? Inventor 2: Last name should preferably be entered in capital letters. Please verify.
13-2-4	Validation messages Priority	Green? Priority 1: please ensure that the priority document is held in a participating digital library and that the receiving Office/International Bureau has been granted the necessary permissions to retrieve the document.
13-2-7	Validation messages Contents	Yellow Images are not in black and white format only
	Validation messages Contents	Green? Figure of the drawings which should accompany the abstract not specified. Please verify.

PCT

13-2-8	Validation messages Fees	Green? Please make sure that the fee schedule utilized is the latest available.
13-2-9	Validation messages Payment	Green? Please ensure that you have a valid deposit account with the receiving Office selected.
13-2-10	Validation messages Annotate	Green? All indications that can be made on the Request form are specifically provided for by the software. Please confirm validity of additional indication.